Impax Asset Management Group plc Trims Stock Holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Impax Asset Management Group plc lessened its stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 20.6% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 135,000 shares of the company’s stock after selling 35,000 shares during the quarter. Impax Asset Management Group plc’s holdings in Prestige Consumer Healthcare were worth $10,542,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Kestra Investment Management LLC purchased a new position in shares of Prestige Consumer Healthcare during the 4th quarter worth approximately $27,000. Huntington National Bank lifted its stake in Prestige Consumer Healthcare by 39.9% during the third quarter. Huntington National Bank now owns 635 shares of the company’s stock worth $46,000 after purchasing an additional 181 shares in the last quarter. International Assets Investment Management LLC boosted its position in shares of Prestige Consumer Healthcare by 7,112.5% during the third quarter. International Assets Investment Management LLC now owns 1,154 shares of the company’s stock worth $83,000 after buying an additional 1,138 shares during the period. Covestor Ltd grew its stake in shares of Prestige Consumer Healthcare by 95.6% in the third quarter. Covestor Ltd now owns 1,338 shares of the company’s stock valued at $96,000 after buying an additional 654 shares in the last quarter. Finally, GAMMA Investing LLC raised its holdings in shares of Prestige Consumer Healthcare by 18.9% in the 4th quarter. GAMMA Investing LLC now owns 1,383 shares of the company’s stock valued at $108,000 after buying an additional 220 shares during the period. 99.95% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on PBH. Sidoti downgraded Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 target price for the company. in a research report on Monday, December 9th. StockNews.com upgraded shares of Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a report on Friday, January 24th. Raymond James upgraded shares of Prestige Consumer Healthcare to a “moderate buy” rating in a report on Thursday, December 19th. DA Davidson boosted their price target on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a “buy” rating in a research note on Friday, February 7th. Finally, Oppenheimer upped their price objective on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an “outperform” rating in a research report on Thursday, February 13th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $92.60.

Prestige Consumer Healthcare Trading Up 0.6 %

NYSE PBH opened at $85.12 on Tuesday. Prestige Consumer Healthcare Inc. has a 52 week low of $62.35 and a 52 week high of $88.36. The firm has a 50 day moving average of $79.53 and a two-hundred day moving average of $76.75. The company has a quick ratio of 2.20, a current ratio of 3.68 and a debt-to-equity ratio of 0.56. The stock has a market capitalization of $4.22 billion, a PE ratio of 19.93, a price-to-earnings-growth ratio of 2.69 and a beta of 0.50.

Prestige Consumer Healthcare (NYSE:PBH) last issued its earnings results on Thursday, February 6th. The company reported $1.22 EPS for the quarter, topping analysts’ consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. As a group, research analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.